Literature DB >> 2163309

Evidence for calcitonin receptor heterogeneity: binding studies with nonhelical analogs.

H Nakamuta1, R C Orlowski, R M Epand.   

Abstract

Binding of the nonhelical salmon calcitonin (sCT) analog, [Gly8,Ala16]-des-Leu19-sCT to membrane preparations from rat brain could be analyzed in terms of two independent binding sites. The high and low affinity binding sites for this analog were named CT-L (L, linear) and CT-H (H, helix), respectively. Although the CT-H type receptor has a low affinity for the nonhelical analogs, it binds the helical sCT with high affinity and therefore represents a CT binding site. The physiological significance for the existence of subtypes of specific CT receptors is not clear. The [Gly8,Ala16]-des-Leu19-sCT suppressed the osteoclastic bone resorption in tissue culture at low concentration (0.1 nM). The dose of [Gly8,Ala16]-des-Leu19-sCT required for this hypocalcemic activity was highly correlated with the binding affinity of this analog to the CT-L receptor subtype. In addition, human CT interacted with the CT-L type receptor at about 100th the concentration of that required for the displacement of sCT. We conclude that binding to the CT-L type receptor is required for hypocalcemic activity in mammals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163309     DOI: 10.1210/endo-127-1-163

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Structure of peptide solutions: a light scattering and numerical study.

Authors:  S U Egelhaaf; V Lobaskin; H H Bauer; H P Merkle; P Schurtenberger
Journal:  Eur Phys J E Soft Matter       Date:  2004-02       Impact factor: 1.890

Review 2.  Central nervous system binding sites for calcitonin and calcitonin gene-related peptide.

Authors:  P M Sexton
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

3.  Degradation and aggregation of human calcitonin in vitro.

Authors:  R H Lu; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

4.  Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies.

Authors:  Yu Tang; Jagdish Singh
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

5.  Interactions of the human calcitonin fragment 9-32 with phospholipids: a monolayer study.

Authors:  Kerstin Wagner; Nicole Van Mau; Sylvie Boichot; Andrey V Kajava; Ulrike Krauss; Christian Le Grimellec; Annette Beck-Sickinger; Frédéric Heitz
Journal:  Biophys J       Date:  2004-07       Impact factor: 4.033

6.  Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy.

Authors:  Ravi Prakash Reddy Nanga; Jeffrey R Brender; Jiadi Xu; Kevin Hartman; Vivekanandan Subramanian; Ayyalusamy Ramamoorthy
Journal:  J Am Chem Soc       Date:  2009-06-17       Impact factor: 15.419

7.  Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity.

Authors:  Weiqiang Cheng; Seetharama Satyanarayanajois; Lee-Yong Lim
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.